# Triana Biomedicines

Source: https://onco.cc/companies/triana-biomedicines/  
OnCo record `triana-biomedicines` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Triana Biomedicines designs molecular glues that make cancer cells destroy their own faulty proteins. Its first drug, TRI-611, removes the ALK fusion protein that drives a subset of lung cancers and has entered human trials.

## Summary

Triana Biomedicines is a Lexington, Massachusetts company with a target-first molecular glue discovery platform that pairs disease targets with the most suitable of more than 600 E3 ubiquitin ligases. Its lead candidate, TRI-611, is an oral, brain-penetrant molecular glue degrader that brings ALK fusion proteins to cereblon independently of the kinase active site, intended to overcome resistance, CNS metastases and tolerability limits of ALK inhibitors in ALK-positive non-small cell lung cancer; it has entered the clinic. A CCNE1 (cyclin E1) degrader programme targets CCNE1-amplified tumours and a subset of HR-positive/HER2-negative breast cancers. Triana launched in April 2022 with 110 million US dollars in total funding (seeded by RA Capital and Atlas Venture, Series A co-led by Lightspeed) and closed a 120 million US dollar Series B in December 2025 co-led by Ascenta Capital and Bessemer Venture Partners.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Lexington, MA
- Type: biotech
- Website: https://trianabio.com/

## Notes

- SEC Form D filings show 42.55 million US dollars sold by April 2022 and 120.06 million sold by December 2025, consistent with tranche-based funding of the announced totals. Founding year from the Form D year of incorporation.

## Sources

- Official website: https://trianabio.com/
- Pipeline: https://trianabio.com/pipeline
- Launch press release (April 2022): https://trianabio.com/press-release-4-6-2022
- Series B press release (December 2025): https://trianabio.com/press-release-12032025-1

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [ALK](https://onco.cc/targets/alk/)
- drugs: [TRI-611](https://onco.cc/drugs/tri-611/)
- trials: [A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC](https://onco.cc/trials/nct07491497/)
- companies: [Atlas Venture](https://onco.cc/companies/atlas-venture/), [Lightspeed Venture Partners](https://onco.cc/companies/lightspeed-venture-partners/), [Logos Capital](https://onco.cc/companies/logos-capital/), [Pfizer Ventures](https://onco.cc/companies/pfizer-ventures/), [RA Capital Management](https://onco.cc/companies/ra-capital/)

---
JSON: https://onco.cc/api/v1/entities/triana-biomedicines.json